Product Description
RE002 is a T cell adoptive immunotherapy for the Treatment of KRAS G12D Mutated Solid Tumors. (Sourced from: https://www.clinicaltrials.gov/study/NCT06546150?term=re002&rank=1)
Mechanisms of Action: Cell Therapy,KRAS G12D
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Henan Cancer Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|